p27Kip1 inhibition of GRB2-SOS formation can regulate Ras activation

Molecular and Cellular Biology

Volumn 23, Issue 11, 2003, Pages 3735-3752

  Moeller, Stephanie J ^a   Head, Elizabeth D ^b,d   Sheaff, Robert J ^a,b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; GUANINE NUCLEOTIDE EXCHANGE FACTOR; GUANINE NUCLEOTIDE EXCHANGE FACTOR SOS; MITOGEN ACTIVATED PROTEIN KINASE; MITOGENIC AGENT; PROTEIN; PROTEIN P27; RAF PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG; CDKN1B PROTEIN, MOUSE; CELL CYCLE PROTEIN; CYCLIN E; ENZYME INHIBITOR; GRB2 PROTEIN, HUMAN; GRB2 PROTEIN, MOUSE; HYBRID PROTEIN; LEPTOMYCIN B; MITOGEN ACTIVATED PROTEIN KINASE KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SOS PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNSATURATED FATTY ACID;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE ACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; TWO HYBRID SYSTEM; YEAST; ANIMAL; CELL LINE; CULTURE MEDIUM; CYTOLOGY; DRUG ANTAGONISM; FIBROBLAST; GENETICS; MACROMOLECULE; METABOLISM; MOUSE; MOUSE MUTANT; PHYSIOLOGY; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL CYCLE PROTEINS; CELL LINE; CULTURE MEDIA, SERUM-FREE; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; ENZYME ACTIVATION; ENZYME INHIBITORS; FATTY ACIDS, UNSATURATED; FIBROBLASTS; GRB2 ADAPTOR PROTEIN; HUMANS; MACROMOLECULAR SUBSTANCES; MAP KINASE SIGNALING SYSTEM; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGENS; PROTEIN BINDING; PROTEIN TRANSPORT; PROTEINS; RAS PROTEINS; RECOMBINANT FUSION PROTEINS; SON OF SEVENLESS PROTEINS; TUMOR SUPPRESSOR PROTEINS; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 0037570624     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.23.11.3735-3752.2003     Document Type: Article

References (78)

1. Alessi, D. R., A. Cuenda, P. Cohen, D. T. Dudley, and A. R. Saltiel. 1995. PD098059 is a specific inhibitor of the activation of MAP kinase kinase in vitro and in vivo. J. Biol. Chem. 270:27489-27494.
2. Barbacid, M. 1990. Ras oncogenes: their role in neoplasia. Eur. J. Clin. Investig. 20:225-235.
3. Bar-Sagi, D., D. Rotin, A. Batzer, V. Mandiyan, and J. Schlessinger. 1993. SH3 domains direct cellular localization of signaling molecules. Cell 74:83-91.
4. Boussiotis, V. A., G. J. Freeman, P. A. Taylor, A. Berezovskaya, I. Grass, B. R. Blazar, and L. M. Nadler. 2000. P27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat. Med. 6:290-296.
5. Buday, L., P. H. Warne, and J. Downward. 1995. Downregulation of the Ras activation pathway by MAP kinase phosphorylation of Sos. Oncogene 11: 1327-1331.
6. Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras. Cancer Res. 59:684-688.
7. Chardin, P., J. H. Camonis, N. W. Gale, L. Van Aelst, J. Schlessinger, M. H. Wigler, and D. Bar-Sagi. 1993. Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2. Science 260:1338-1343.
8. Cheng, A. M., T. M. Saxton, R. Sakai, S. Kulkarni, G. Mbamalu, W. Vogel, C. G. Tortorice, R. D. Cardiff, J. C. Cross, W. J. Muller, and T. Pawson. 1998. Mammalian Grb2 regulates multiple steps in embryonic development and malignant transformation. Cell 95:793-803.
9. Kip1 CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 18:1571-1583.
10. ras desensitization. J. Biol. Chem. 270:1485-1488.
11. Clurman, B., and J. M. Roberts. 1998. Cell cycle control: an overview, p. 175-193. In B. Vogelstein and K. W. Kinzler (ed.), The genetic basis of human cancer, 1st ed. McGraw-Hill, New York, N.Y.
12. Kip1 for restriction point control of the fibroblast cell cycle. Science 272:877-880.
13. Kip1-deficient cells. Curr. Biol. 9:163-173.
14. Corbolan-Garcia, S., S.-S. Yang, K. R. Degenhardt, and D. Bar-Sagi. 1996. Identification of the MAP kinase phosphorylation sites on human Sos1 that regulate interaction with Grb2. Mol. Cell. Biol. 10:5674-5682.
15. Daly, R. J., M. D. Binder, and R. L. Sutherland. 1994. Overexpression of the Grb2 gene in human breast cancer cell lines. Oncogene 9:2723-2727.
16. 1 checkpoint control. Cell 82:675-684.
17. 1 phase in BALB/c 3T3 cells. Mol. Cell. Biol. 14:5441-5449.
18. Dudley, D. T., L. Pang, S. J. Decker, A. J. Bridges, and A. R. Saltiel. 1995. A synthetic inhibitor of the MAP kinase cascade. Proc. Natl. Acad. Sci. USA 92:7686-7689.
19. Egan, S. E., B. W. Giddings, M. W. Brooks, L. Buday, A. M. Sizeland, and R. A. Weinberg. 1993. Association of SOS Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. Nature 363:45-51.
20. Ewen, M. E. 2000. Relationship between Ras pathways and cell cycle control. Progress Cell Cycle Res. 4:1-17.
21. Kip1-deficient mice. Cell 85:733-744.
22. Kip1 is haplo-insufficient for tumour suppression. Nature 396:177-180.
23. Frame, S., and A. Balmain. 2000. Integration of positive and negative growth signals during ras pathway activation in vivo. Curr. Opin. Genet. Dev. 10: 106-113.
24. kip1 and degree of malignancy in human breast and colorectal cancers. Proc. Natl. Acad. Sci. USA 94:6380-6385.
25. 1 cell cycle progression. J. Biol. Chem. 274:22033-22038.
26. Hanahan, D., and R. A. Weinberg. 2000. The hallmarks of cancer. Cell 100:57-70.
27. Heldin, C., and B. Westermark. 1999. Mechanism of action and in vivo role of PDGF. Phys. Rev. 79:1283-1316.
28. Hengst, L., V. Dulic, J. M. Slingerland, E. Lees, and S. I. Reed. 1994. A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc. Natl. Acad. Sci. USA 91:5291-5295.
29. Howell, K. E., E. Devaney, and J. Gruenberg. 1989. Subcellular fractionation of tissue culture cells. Trends Biol. Sci. 14:44-47.
30. Kip1 on serine 10 is required for its binding to CRM1 and nuclear export. J. Biol. Chem. 277:14355-14358.
31. Kip1, increases its protein stability. J. Biol. Chem. 275:25146-25154.
32. Katz, M. E., and F. McCormick. 1997. Signal transduction from multiple Ras effectors. Curr. Opin. Genet. Dev. 7:75-79.
33. Kip1. Cell 85:721-732.
34. 1 in mammalian cells: inhibition of cyclin E-dependent kinase by transforming growth factor beta. Science 260:536-539.
35. LaBaer, J., M. D. Garrett, L. F. Stevenson, J. M. Slingerland, C. Sandhu, H. S. Chou, A. Fattaey, and E. Harlow. 1997. New functional activities for the p21 family of inhibitors. Genes Dev. 11:847-862.
36. Ladha, M. H., K. Y. Lee, T. M. Upton, M. F. Reed, and M. E. Ewen. 1998. Regulation of exit from quiescence by p27 and cyclin D1-CDK4. Mol. Cell. Biol. 18:6605-6615.
37. ras activation. J. Biol. Chem. 270:25320-25323.
38. + T cells. Science 271:1272-1276.
39. Li, N., A. Batzer, R. Daly, V. Yajkik, E. Skolnik, P. Chardin, D. Bar-Sagi, B. Margolis, and J. Schlessinger. 1993. Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling. Nature 363:85-88.
40. kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am. J. Pathol. 154: 313-323.
41. Lowenstein, E. J., R. J. Daly, A. G. Batzer, W. Li, B. Margolis, R. Lammers, A. Ullrich, E. Y. Skolnik, D. Bar-Sagi, and J. Schlessinger. 1992. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 70:431-442.
42. Mansour, S. J., W. T. Matten, A. S. Hermann, J. M. Candia, S. Rong, K. Fukasawa, G. F. VandeWoude, and N. G. Ahn. 1994. Transformation of mammalian cells by consitutively active MAP kinase kinase. Science 265: 966-970.
43. Morgan, D. O. 1997. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell Dev. Biol. 13:261-291.
44. Mulcahy, L. S., M. R. Smith, and D. W. Stacey. 1985. Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells. Nature 313:241-243.
45. Muller, D., C. Bouchard, B. Rudolph, P. Steiner, I. Stuckmann, R. Saffrich, W. Ansorge, W. Huttner, and M. Eilers. 1997. CDK2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclinE/cdk2 complexes. Oncogene 15:2561-2576.
46. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85:707-720.
47. kip1 cyclin-CDK kinase inhibitor prevented by rapamycin. Nature 372:570-573.
48. Olivier, J. P., T. Raabe, M. Henkenmeyer, B. Dickson, G. Mbamalu, B. Margolis, J. Schlessinger, E. Hafen, and T. Pawson. 1993. A Drosophila SH2-SH3 adaptor protein implicated in coupling the sevenless tyrosine kinase to an activator of ras guanine nucleotide exchange, Sos. Cell 73:179-191.
49. Pagano, M., S. W. Tam, A. M. Theodoras, P. Beer-Romero, G. Del Sal, V. Chau, P. R. Yew, G. F. Draetta, and M. Rolfe. 1995. Role of the ubiquitinproteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682-685.
50. Peeper, D. S., T. M. Upton, M. H. Ladha, E. Neuman, J. Zalvide, R. Bernards, J. A. DeCaprio, and M. E. Ewen: 1997. Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature 386:177-181.
51. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59-66.
52. kip1, a cyclin-CDK inhibitor, links transforming growth factor beta and contact inhibition to cell cycle arrest. Genes Dev. 8:9-22.
53. Rodier, G., A. Montagnoli, L. Di Marcotullio, P. Coulombe, G. F. Draetta, M. Pagano, and S. Meloche. 2001. p27 cytoplasmic localization is regulated by phosphorylation on Ser 10 and is not a prerequisite for its proteolysis. EMBO J. 20:6672-6682.
54. Rozakis-Adcock, M., J. McGlade, G. Mbamalu, G. Pelicci, R. Daly, W. Li, A. Batzer, S. Thomas, J. Brugge, P. G. Pelicci, J. Schlessinger, and T. Pawson. 1992. Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature 360:689-692.
55. Sanchez-Beato, M., F. I. Camacho, J. C. Martinez-Montero, A. I. Saez, R. Villuendas, L. Sanchez-Verde, J. F. Garcia, and M. A. Piris. 1999. Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. p27/KIP1-cyclin D3 colocalization in tumor cells. Blood 94:765-772.
56. Satoh, T., M. Endo, M. Nakafuku, S. Nakamura, and Y. Kaziro. 1990. Platelet-derived growth factor stimulates formation of active p21ras-GTP complex in Swiss mouse 3T3 cells. Proc. Natl. Acad. Sci. USA 87:5993-5997.
57. Satoh, T., M. Endo, M. Nakafuku, T. Akiyama, T. Yamamoto, and Y. Kaziro. 1990. Accumulation of p21ras-GTP in response to stimulation with EGF and oncogene products with tyrosine kinase activity. Proc. Natl. Acad. Sci. USA 87:7926-7929.
58. Schwartz, R. H. 1997. T cell clonal anergy. Curr. Opin. Immunol. 9:351-357.
59. Kip1 and its alterations in tumor cells: a review. J. Cell. Phys. 183:18-27.
60. Kip1. Genes Dev. 11:1464-1478.
61. 1 cyclin-dependent kinases. Genes Dev. 9:1149-1153.
62. 1-phase progression. Genes Dev. 13:1501-1512.
63. Shields, J. M., K. Pruitt, A. McFall, A. Shaub, and C. J. Der. 2000. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol. 10:147-154.
64. Ras1 activation and binds to sevenless and Sos protein in vitro. Cell 73:169-177.
65. Singh, S. P., J. Lipman, H. Goldman, F. H. Ellis, Jr, L. Aizenman, M. G. Cangi, S. Signoretti, D. S. Chiaur, M. Pagano, and M. Loda. 1998. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res. 58:1730-1735.
66. Smitherman, M., K. Lee, J. Swanger, R. Kapur, and B. E. Clurman. 2000. Characterization and targeted disruption of murine Nup50, a p27(Kip1)interacting component of the nuclear pore complex. Mol. Cell. Biol. 20: 5631-5642.
67. Kip1. J. Biol. Chem. 276:12084-12090.
68. 1 cyclin expression in breast cancer cells. Oncogene 16:2865-2878.
69. Kip1 downregulation, passage through the restriction point, and entry into S phase in growth factor-stimulated NIH 3T3 fibroblasts. Mol. Cell. Biol. 17:5348-5358.
70. Taylor, S. J., and D. Shalloway. 1996. Cell cycle-dependent activation of Ras. Curr. Biol. 6:1621-1627.
71. Kip1 is instigated by Jab1. Nature 398:160-165.
72. 1-cyclin-CDK protein kinase activity, is related to p21. Cell 78:67-74.
73. Tsihlias, J., L. Kapusta, and J. Slingerland. 1999. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu. Rev. Med. 50:401-423.
74. Verbeek, B. S., S. S. Adriaansen-Slot, G. Rijksen, and T. M. Vroom. 1997. Grb2 overexpression in nuclei and cytoplasm of human breast cells: a histochemical and biochemical study of normal and neoplastic mammary tissue specimens. J. Pathol. 183:195-203.
75. Vlach, J., S. Hennecke, and B. Amati. 1997. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J. 16:5334-5344.
76. Waters, S. B., K. Yamauchi, and J. E. Pessin. 1995. Insulin-stimulated dissociation of the Sos-Grb2 complex. Mol. Cell. Biol. 15:2791-2799.
77. Zarich, N., J. L. Oliva, R. Jorge, E. Santos, and J. M. Rojas. 2000. The isoform-specific stretch of hSos1 defines a new Grb2-binding domain. Oncogene 19:5872-5883.
78. Kip1, a cyclin-dependent kinase inhibitor. Biochem. Biophys. Res. Commun. 274:37-42.